Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22070743 | 0.88 | MEN1 (0.49) | MEN1KMT2AALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL22070745 | 0.88 | MEN1 (0.49) | MEN1KMT2AALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL17040985 | 0.88 | MEN1 (0.49) | MEN1KMT2AALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL22816571 | 0.87 | ALDH1A1 (0.54) | MEN1KMT2AALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL1169921 | 0.87 | ALDH1A1 (0.54) | MEN1KMT2AALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL6642114 | 0.87 | ALDH1A1 (0.54) | MEN1KMT2AALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL9293451 | 0.86 | MEN1 (0.48) | MEN1KMT2AALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL2485308 | 0.86 | MEN1 (0.48) | MEN1KMT2AALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL2485306 | 0.86 | MEN1 (0.48) | MEN1KMT2AALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL2487028 | 0.86 | MEN1 (0.48) | MEN1KMT2AALDH1A1MAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10918622-B2 | Compounds useful as kinase inhibitors | LOXO ONCOLOGY, INC. (US) | 2021-02-16 | — | — | US | disclosed |
| US-20200392223-A1 | IL-17A ACTIVITY INHIBITOR AND USE THEREOF | TOKAI UNIVERSITY EDUCATIONAL SYSTEM (JP) | 2020-12-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10918622-B2 | Compounds useful as kinase inhibitors | BTK, ABL1, LCK | MEN1 2243/4885KMT2A 688/4885ALDH1A1 4454/4885 |
| US-20200392223-A1 | IL-17A ACTIVITY INHIBITOR AND USE THEREOF | IL17A, IL23R, IL15RA | MEN1 4122/4885KMT2A 3037/4885ALDH1A1 2384/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.